Log in to search using one of your social media accounts:

 

Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS ® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma
ENDEAVOR Study Long-Term Data Shows KYPROLIS and Dexamethasone Reduced the Risk of Death by 24 Percent Versus Velcade® (Bortezomib) and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 9.0 Months Longer Than Patients Receiving Velcade and Dexamethasone Long-Term Follow-Up Demonstrated Consistent Safety Profile THOUSAND OAKS, Calif., Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive results from a post-hoc analysis requested by the U.S. Food and Drug Administration (FDA) of the Phase 3 head-to-head ENDEAVOR trial, which followed patients for at least three y...
Source: Amgen News Release - August 30, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS ® (Carfilzomib) Label
FDA Sets PDUFA Target Action Date of April 30, 2018 THOUSAND OAKS, Calif., Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) based on the overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial demonstrating that KYPROLIS® (carfilzomib) and dexamethasone (Kd) reduced the risk of death by 21 percent and increased OS by 7.6 months versus Velcade® (bortezomib) and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (median OS 47.6 mon...
Source: Amgen News Release - August 30, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Overall Survival Analysis From KYPROLIS ® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology
KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Compared to Velcade® (bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients KYPROLIS is the First and Only Multiple Myeloma Therapy Proven to Extend Overall Survival in a Head-to-Head Comparison With a Current Standard of Care in the Relapsed Setting THOUSAND OAKS, Calif., Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published online first in The Lancet Oncology. Data showed that KYPROLIS® (...
Source: Amgen News Release - August 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Reduced Retreatment Dose Feasible in Relapsed, Refractory Multiple Myeloma
Prolonged use of bortezomib after treatment with combined bortezomib plus dexamethasone did not result in any significant benefit for patients with relapsed/refractory multiple myeloma compared with bortezomib plus dexamethasone alone, but this less dose-intensive approach could be a feasible option for patients who cannot tolerate the standard regimen. (Source: CancerNetwork)
Source: CancerNetwork - August 19, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

U.S. court upholds Takeda patent on cancer drug Velcade
(Reuters) - A U.S. appeals court ruled on Monday that a patent on Takeda Pharmaceutical Co Ltd's cancer treatment Velcade is valid, pushing back the date when generic drug makers including Teva Pharmaceutical Industries Ltd and Mylan NV will be allowed to launch lower-cost versions of the drug in the United States. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS ® (Carfilzomib) Label
Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients THOUSAND OAKS, Calif., July 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a variation to the marketing application to the European Medicines Agency (EMA) to include overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in the product information fo...
Source: Amgen News Release - July 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New Data At 22nd Congress of the European Hematology Association
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma New Subset Analysis Demonstrates BLINCYTO® (Blinatumomab) More Than Doubled Median Overall Survival Versus Standard of Care Chemotherapy in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage Oral Presentation of New Data From Head-to-Head Phase 3 Study of XGEVA® (Denosumab) Versus Zoledronic Acid in Time to First On-Study Skeletal...
Source: Amgen News Release - June 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Significant Toxicity, Infection Risk Associated With Elo-RVD in Myeloma
In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Multiple Myeloma News Source Type: news

Decarboxylative borylation
We describe a simple and practical method to rapidly access densely functionalized alkyl boronate esters from abundant carboxylic substituents. This broad-scope nickel-catalyzed reaction uses the same activating principle as amide bond formation to replace a carboxylic acid moiety with a boronate ester. Application to peptides allowed expedient preparations of α-amino boronic acids, often with high stereoselectivity, thereby facilitating synthesis of the alkyl boronic acid drugs Velcade and Ninlaro as well as a boronic acid version of the iconic antibiotic vancomycin. The reaction also enabled the discovery and exten...
Source: ScienceNOW - June 8, 2017 Category: Science Authors: Li, C., Wang, J., Barton, L. M., Yu, S., Tian, M., Peters, D. S., Kumar, M., Yu, A. W., Johnson, K. A., Chatterjee, A. K., Yan, M., Baran, P. S. Tags: Chemistry, Online Only r-articles Source Type: news

Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells
Increased protein translation in cells and various factors in the tumor microenvironment can induce endoplasmic reticulum (ER) stress, which initiates the unfolded protein response (UPR). We have previously reported that factors released from cancer cells mounting a UPR induce a de novo UPR in bone marrow–derived myeloid cells, macrophages, and dendritic cells that facilitates protumorigenic characteristics in culture and tumor growth in vivo. We investigated whether this intercellular signaling, which we have termed transmissible ER stress (TERS), also operates between cancer cells and what its functional consequenc...
Source: Signal Transduction Knowledge Environment - June 6, 2017 Category: Science Authors: Rodvold, J. J., Chiu, K. T., Hiramatsu, N., Nussbacher, J. K., Galimberti, V., Mahadevan, N. R., Willert, K., Lin, J. H., Zanetti, M. Tags: STKE Research Articles Source Type: news

Janssen reports positive results from two Phase III combination trials of Darzalex
Janssen Research& Development has reported positive results from the updated Phase III CASTOR and POLLUX clinical trials of Darzalex (daratumumab) combined with bortezomib and dexamethasone or lenalidomide and dexamethasone to treat patients with mu … (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2017 Category: Pharmaceuticals Source Type: news

RVD Plus Transplantation Delayed Progression in Myeloma
Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - April 12, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Velcade (Bortezomib) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 11, 2017 Category: Drugs & Pharmacology Source Type: news

‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients
Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Amgen Presents Overall Survival Data From KYPROLIS ® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop
Late-Breaking Presentation to Show Overall Survival Benefit of KYPROLIS Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival THOUSAND OAKS, Calif., March 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myelom...
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New KYPROLIS ® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop
Detailed Results From Phase 3 Head-to-Head ENDEAVOR Trial Show KYPROLIS Significantly Improved Overall Survival Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients Late-Breaking Results From Largest International Trial Conducted in Multiple Myeloma Show XGEVA was Non-Inferior Versus Zoledronic Acid in Delaying Bone Complications THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the KYPROLIS® (carfilzomib) and XGEVA® (denosumab) clinical development programs will be presented at the 16th International Myeloma ...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study
(Reuters) - Patients with relapsed multiple myeloma treated with Amgen Inc's Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co's Velcade, according to data from a late-stage study released by Amgen on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - February 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Phase 3 Head-to-Head Trial Showed KYPROLIS ® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients
First-and-Only Head-to-Head Study Comparing Proteasome Inhibitors to Demonstrate Statistically Significant Improved Overall Survival Detailed Results Will be Presented at the 16th International Myeloma Workshop (IMW) in New Delhi THOUSAND OAKS, Calif., Feb. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS® (carfilzomib) and dexamethasone (Kd)...
Source: Amgen News Release - February 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Bortezomib Triplet Improves Outcomes in Newly Diagnosed Multiple Myeloma
Adding bortezomib to lenalidomide and dexamethasone improved progression-free and overall survival in patients with newly diagnosed multiple myeloma who were not planned for immediate stem-cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - January 18, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

HDAC6 Inhibitor Shows Activity in Relapsed, Refractory Myeloma
The combination of bortezomib and dexamethasone with 160 mg daily ricolinostat, a selective histone deacetylase 6 inhibitor, was well tolerated and active in patients with relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - January 17, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Frontline Triplet With Bortezomib: New Standard in Myeloma? Frontline Triplet With Bortezomib: New Standard in Myeloma?
Bortezomib added to lenalidomide plus dexamethasone significantly increased both progression-free and overall survival in multiple myeloma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Results of major myeloma treatment trial published in The Lancet
(SWOG) The addition of bortezomib to a standard two-drug regimen for multiple myeloma patients significantly lengthened the time before their cancer returned, and significantly lengthened their lives, according to clinical trial results in The Lancet. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 22, 2016 Category: Cancer & Oncology Source Type: news

FDA Approves Daratumumab Combinations for Previously Treated Myeloma
The FDA has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 2, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Darzalex (daratumumab) Approved by FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
HORSHAM, PA, Nov. 21, 2016 – Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2016 Category: Drugs & Pharmacology Source Type: news

Combination Improved Panobinostat Tolerability in Multiple Myeloma
Patients with multiple myeloma may have improved tolerance of panobinostat when combined with low-dose thalidomide and subcutaneous bortezomib, according to the results of the phase I/II MUK-six trial. (Source: CancerNetwork)
Source: CancerNetwork - November 16, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selexinor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news

Positive Top-Line Phase 2b STORM Results Reported, with Plans for Development Path of Selinexor for the Treatment of Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced the initiation of the STORM study (Selinexor Treatment of Refractory Myeloma) on September 6, 2016. STORM is a multi-center, single-arm Phase 2 study of selinexor (KPT-330) in heavily-pretreated patients with quad-refractory multiple myeloma. Selinexor, the company's lead, novel, oral Selective Inhibitor of Nuclear Export / SINE ™ compound, will be evaluated in combination with low-dose dexamethasone in multiple myeloma patients whose disease was refractory to treatment with bortezomib (Velcade®), lenalidomide (Revlimid...
Source: International Myeloma Foundation - September 28, 2016 Category: Hematology Source Type: news

Amgen's multiple myeloma drug falls short in new-patient study
(Reuters) - Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, did not fare better than Takeda Pharmaceutical Co Ltd's older therapy Velcade in a study involving patients who had not yet been treated for the disease. (Source: Reuters: Health)
Source: Reuters: Health - September 27, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Amgen Announces Top-Line Results From Phase 3 KYPROLIS ® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients
Amgen to Hold Analyst Call Today at 8:30 a.m. ET THOUSAND OAKS, Calif., Sept. 27, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of KYPROLIS® (carfilzomib), melphalan and prednisone (KMP) versus Velcade® (bortezomib), melphalan and prednisone (VMP) for 54 weeks in patients with newly diagnosed multiple myeloma who were ineligible for hematopoietic stem-cell transplant. The trial did not meet the primary endpoint of superiority in progression-free survival (PFS) (median PFS 22.3 months for KMP versus 22...
Source: Amgen News Release - September 27, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

GlycoMimetics starts phase one trial of GMI-1271 to treat multiple myeloma
US-based biotechnology company GlycoMimetics has commenced the phase one clinical trial of GMI-1271, combined with bortezomib-based chemotherapy to treat multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - September 14, 2016 Category: Pharmaceuticals Source Type: news

Daratumumab Improves PFS in Multiple Myeloma Daratumumab Improves PFS in Multiple Myeloma
Daratumumab added to bortezomib and dexamethasone improves progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (MM), according to results from the CASTOR trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 2, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Daratumumab Combination Lengthened PFS for Heavily Pretreated Myeloma
Adding the CD38-targeting monoclonal antibody daratumumab to bortezomib and dexamethasone resulted in significantly improved progression-free survival in patients with heavily pretreated multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - September 1, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Head-to-Head Phase 3 Trial Demonstrated Superiority of Kyprolis and Dexamethasone Over Velcade® (Bortezomib) and Dexamethasone in Patients with Relapsed Multiple Myeloma New Indication Allows Kyprolis to be Used in Combination with Dexamethasone Alo... Biopharmaceuticals, Oncology, RegulatoryAmgen, Kyprolis, Carfilzomib, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 4, 2016 Category: Pharmaceuticals Source Type: news

European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Head-to-Head Phase 3 Trial Demonstrated Superiority of Kyprolis and Dexamethasone Over Velcade® (Bortezomib) and Dexamethasone in Patients with Relapsed Multiple Myeloma New Indication Allows Kyprolis to be Used in Combination with Dexamethasone Alone for Appropriate Patients THOUSAND OAKS, Calif., July 3, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least...
Source: Amgen News Release - July 4, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

European Commission Approves Extended Indication For Amgen's Kyprolis ® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Head-to-Head Phase 3 Trial Demonstrated Superiority of Kyprolis and Dexamethasone Over Velcade® (Bortezomib) and Dexamethasone in Patients with Relapsed Multiple Myeloma New Indication Allows Kyprolis to be Used in Combination with Dexamethasone Alone for Appropriate Patients THOUSAND OAKS, Calif., July 3, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least...
Source: Amgen News Release - July 3, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Bortezomib-Based Chemo Ups AL Cardiac Amyloidosis SurvivalBortezomib-Based Chemo Ups AL Cardiac Amyloidosis Survival
Heart failure due to light-chain amyloidosis is "one of the most devastating diagnoses a cardiologist may give a patient," one expert observes. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
Cumulative Rates of Complete Response or Better Increased Over Time in Patients Treated With Kyprolis in Combination With Lenalidomide and Dexamethasone (KRd) In a Post-Hoc Analysis, Treatment With KRd for 18 Months Reduced Risk of Progression or Death by 42 Percent During That Period Additional Analyses Showed Kyprolis Plus Dexamethasone (Kd) was Superior to Bortezomib Plus Dexamethasone (Vd) Across Patient Populations THOUSAND OAKS, Calif., June 10, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of c...
Source: Amgen News Release - June 10, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New Analyses From Pivotal Phase 3 Studies Show Kyprolis ® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
Cumulative Rates of Complete Response or Better Increased Over Time in Patients Treated With Kyprolis in Combination With Lenalidomide and Dexamethasone (KRd) In a Post-Hoc Analysis, Treatment With KRd for 18 Months Reduced Risk of Progression or Death by 42 Percent During That Period Additional Analyses Showed Kyprolis Plus Dexamethasone (Kd) was Superior to Bortezomib Plus Dexamethasone (Vd) Across Patient Populations THOUSAND OAKS, Calif., June 10, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of c...
Source: Amgen News Release - June 10, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
Pivotal Head-to-Head ENDEAVOR Study Shows Kyprolis Plus Dexamethasone Doubled Progression-Free Survival Compared to Velcade® (Bortezomib) and Dexamethasone THOUSAND OAKS, Calif., May 27, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis® (carfilzomib) to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. "In the first ever ...
Source: Amgen News Release - May 27, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 28, 2016 Category: Science Source Type: news

TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors
(University of Texas M. D. Anderson Cancer Center) A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by the University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 28, 2016 Category: Cancer & Oncology Source Type: news

The U.S. Throws Out $3 Billion In Cancer Drugs Every Year
(Reuters Health) - U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a recent paper suggests. Researchers focused on 20 expensive medicines that are given by injection or intravenous drip and require doses adjusted based on the patient’s body size. Often, the packages contain much more medicine than patients need, and the leftovers wind up in the trash. Even when much of the medicine goes in the garbage, patients pay for the ...
Source: Science - The Huffington Post - March 28, 2016 Category: Science Source Type: news

Tx Trio Ups PFS in Heavily Pretreated Myeloma (CME/CE)
(MedPage Today) -- Farydak-Velcade-dexamethasone combo confers 8-month survival advantage (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2016 Category: Hematology Source Type: news

FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Pivotal Head-To-Head ENDEAVOR Study Shows Kyprolis and Dexamethasone Doubled Progression-Free Survival Versus Velcade® (Bortezomib) and Dexamethasone Kyprolis Label Expansion Represents Critical Advancement for Patients With Relapsed or Refractory Multiple Myeloma, Offering New Option For Backbone Therapy Approval Expands Kyprolis Indication and Converts Monotherapy Indication to Full Approval THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (...
Source: Amgen News Release - January 21, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news